Potential Treatment for Early Onset Alzheimer’s…Currently Enrolling

Description

A global clinical research study assessing the effectiveness and safety of an investigational medication designed to slow the progression of early Alzheimer’s disease.

The ENGAGE study is split into two phases: a placebo-controlled phase, and an optional long-term extension phase.

In the placebo-controlled phase, eligible participants will have a 2-in-3 chance of receiving the investigational medication and a 1-in-3 chance of receiving the placebo.

Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease…Ongoing

A Randomized, Placebo controlled, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease. (Prodromal AD)

This is an 18 month study in which subjects that screen and qualify will go onto the program taking the investigation medication by mouth once daily.

Dementia with Lewy Bodies (DLB) Research Study…Ongoing

Dementia with Lewy Bodies (DLB) affects over 1 million people in the United States. It is caused by the buildup of abnormal protein clusters, known as “Lewy Bodies,” within the brain and is characterized by fluctuations in cognitive ability, particularly alertness and attention. Many dementia with Lewy Bodies patients also have visual hallucinations and REM sleep behavior disorder.

Parkinson’s Research Study…Ongoing Study

Most individuals with Parkinson’s disease use levodopa as treatment. It is usually taken in pill form, however long-term usage can lessen the effectiveness of the drug leading to off episodes. In these off episodes, individuals with Parkinson’s suffer from slowness, stiffness and tremors. CVT-301, the medication being evaluated in this study, is a powder form [...]
Eisai / Mild Cognitive Impairment or Mild Alzheimer’s Disease

Eisai / Mild Cognitive Impairment or Mild Alzheimer’s Disease…Ongoing Study

What is Mild Cognitive Impairment (MCI)?

Mild Cognitive Impairment is a condition in which a person has memory loss or thinking problems that are worse than those caused by normal aging, but not bad enough to interfere with daily activities.  A person with MCI has a higher risk of developing Alzheimer’s disease,

Mild to Moderate Alzheimer’s Disease Treated with Donepezil…Ongoing Study

Randomized, double-blind, placebo-controlled, fixed dose study of Lu AE58054 in patients with mild to moderate Alzheimer’s disease treated with Donepezil.

This is a 28 week study in which qualified participants will take the investigational medication or placebo ( a dummy capsule without an active ingredient ) once daily by mouth.

Potential patients must have been receiving a drug containing Donepezil for the last 6 months,

Nerve sonography to detect peripheral nerve involvement in vasculitis syndromes

Background: We sought to determine the usefulness of sonography in the detection of nerve involvement in patients with vasculitic neuropathy.

 

Methods: We enrolled 16 consecutive patients with vasculitic neuropathy (11 systemic vasculitis and 5 single organ peripheral nerve vasculitis), who met the diagnostic criteria of the Peripheral Nerve Society,

Rapid screening for inflammatory neuropathies by standardized clinical criteria

Background: Delay in recognition and treatment of inflammatory neuropathies increases morbidity and mortality. We have developed and standardized 3 clinical screening criteria that rapidly detect inflammatory neuropathies.

 

Methods: We reviewed all patients with definite large fiber neuropathy in 2 different patient populations: 1 from a private neurology clinic and the other from a tertiary care center.

Frequent Migraine Prevention Study…Ongoing Study

Description

A study to evaluate an investigational drug designed to inhibit receptors that are believed to contribute to migraine attacks.

This study lasts up to 55 weeks, in which participants will be screened, go through two phases of treatment and have a follow-up visit.

Study Treatment Phase – Part One – 12 Weeks

Participants will be randomly assigned to receive the investigational drug or a placebo.